Strides Shasun today announced that its wholly owned subsidiary Strides Pharma Global has received approval for Cyproheptadine Hydrochloride Tablets USP, 4 mg from the United States Food & Drug Administration (US FDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck & Co. Inc.
According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately USD 20 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.
The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.
Shares of the company declined Rs 8.1, or 1.26%, to trade at Rs 633.75. The total volume of shares traded was 15,613 at the BSE (11.47 a.m., Thursday).